Literature DB >> 2820475

Differential formation of hydroxyl radicals by adriamycin in sensitive and resistant MCF-7 human breast tumor cells: implications for the mechanism of action.

B K Sinha1, A G Katki, G Batist, K H Cowan, C E Myers.   

Abstract

Adriamycin-stimulated formation of .OH in sensitive and resistant subline of human breast tumor cells (MCF-7) has been examined by electron spin resonance spectroscopy. It was shown that adriamycin significantly stimulated the formation of .OH spin adducts [5,5-dimethyl-1-pyrroline N-oxide (DMPO)-OH] in the sensitive cells but not in the resistant cells. By use of spin-broadening techniques and inhibition of .OH with high molecular weight poly(ethylene glycol), which does not enter intact cells, it was shown that 60-65% of adriamycin-induced .OH were located extracellularly and were metal ion dependent since they were decreased in the presence of desferal. Furthermore, superoxide dismutase and catalase, enzymes that detoxify superoxide and hydrogen peroxide, also significantly inhibited adriamycin-induced .OH formation and protected against the cytotoxicity of adriamycin. The differential .OH formation in these two cell lines is not due to diminished activities of flavin-dependent activating enzymes nor decreased accumulation of the drug in the cells but appears to be related to enhanced activities of detoxifying enzymes, particularly, glutathione peroxidases in the resistant cells.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2820475     DOI: 10.1021/bi00387a006

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  30 in total

Review 1.  Resistance to cytostatic drugs at the cellular level.

Authors:  C P Vendrik; J J Bergers; W H De Jong; P A Steerenberg
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

2.  Evolutionary dynamics in cancer therapy.

Authors:  Jessica J Cunningham; Robert A Gatenby; Joel S Brown
Journal:  Mol Pharm       Date:  2011-08-23       Impact factor: 4.939

3.  Stability of adriamycin-induced DNA adducts and interstrand crosslinks.

Authors:  A van Rosmalen; C Cullinane; S M Cutts; D R Phillips
Journal:  Nucleic Acids Res       Date:  1995-01-11       Impact factor: 16.971

4.  Photodynamic enhancement of doxorubicin cytotoxicity.

Authors:  K W Lanks; J P Gao; T Sharma
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

5.  Effect of nitric oxide on the anticancer activity of the topoisomerase-active drugs etoposide and adriamycin in human melanoma cells.

Authors:  Birandra K Sinha; Ashutosh Kumar; Suchandra Bhattacharjee; Michael G Espey; Ronald P Mason
Journal:  J Pharmacol Exp Ther       Date:  2013-09-18       Impact factor: 4.030

6.  Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein.

Authors:  G J Zaman; J Lankelma; O van Tellingen; J Beijnen; H Dekker; C Paulusma; R P Oude Elferink; F Baas; P Borst
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-15       Impact factor: 11.205

7.  Aerobic inactivation of fumarate reductase from Escherichia coli by mutation of the [3Fe-4S]-quinone binding domain.

Authors:  G Cecchini; H Sices; I Schröder; R P Gunsalus
Journal:  J Bacteriol       Date:  1995-08       Impact factor: 3.490

8.  Optimizing the time of Doxil injection to increase the drug retention in transplanted murine mammary tumors.

Authors:  Shaojin You; Lian Zuo; Wei Li
Journal:  Int J Nanomedicine       Date:  2010-04-07

9.  Epirubicin exhibits potent anti-tumor activity in an animal model of malignant glioma when administered via controlled-release polymers.

Authors:  Violette Renard Recinos; Kimon Bekelis; Shira G Ziegler; Ditty Vick; Samuel Hertig; Betty M Tyler; Khan W Li; Thomas Kosztowski; Federico G Legnani; Henry Brem; Alessandro Olivi
Journal:  J Neurooncol       Date:  2009-08-20       Impact factor: 4.130

10.  Enhanced antitumor activity of combinations of free and HPMA copolymer-bound drugs.

Authors:  J Hongrapipat; P Kopecková; S Prakongpan; J Kopecek
Journal:  Int J Pharm       Date:  2007-09-22       Impact factor: 5.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.